Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 25 Nov 2020

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Stephen Padilla, 10 Nov 2020
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.

Delayed denosumab injections tied to reduced BMD response

13 Apr 2020

Delays in injections of denosumab lead to suboptimal bone mineral density (BMD) response at both spine and total hip, results of a recent study have shown.

Electronic medical records from two academic hospitals from 2010 to 2017 were used to examine the association between delayed denosumab infections and BMD change. Patients aged >45 years who used at least two doses of 60-mg denosumab were included in the analysis.

Medication coverage ratio (MCR) was utilized to assess adherence to denosumab. Good adherence was defined as a dosing interval ≤7 months (MCR ≥93 percent), moderate adherence an interval of 7–10 months (MCR 75–93 percent), and poor adherence an interval ≥10 months (MCR ≤75 percent).

Annualized percent BMD change at the lumbar spine, total hip and femoral neck from baseline was the primary outcome.

A total of 938 denosumab injections among 151 patients (mean age, 69 years; 95 percent female) were identified. Good adherence among patients resulted in a 3.9-percent annualized BMD increase at the lumbar spine compared with 3.0 percent for moderate or 1.4 percent for poor adherence (ptrend=0.002).

In addition, those with good adherence showed a 2.1-percent annualized BMD increase at the total hip compared with 1.3 percent for moderate or 0.6 percent for poor adherence (ptrend=0.002).

“Discontinuation of denosumab leads to a rapid reversal of its therapeutic effect,” the authors said. “Strategies to improve the timely administration of denosumab in real-world settings are needed.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 25 Nov 2020

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Stephen Padilla, 10 Nov 2020
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.